Logo image
Back
Cancer Immunology
Book chapter

Cancer Immunology

Sander Bekeschus, Jean-Michel Pouvesle, Alexander Fridman and Vandana Miller
Comprehensive Clinical Plasma Medicine, pp 409-419
05 May 2018
DOI: https://doi.org/10.1007/978-3-319-67627-2_24

Abstract

Damage-associated molecular patterns DAMPs ICD Immunogenic cell death Oncology Plasma oncotherapy
Cold physical plasma is receiving increasing attention in oncology. Generation of a plethora of different reactive species is a major trait of cold plasmas. Reactive species and mitochondria have been the focus of cancer and cell death research for many decades. This links the field of plasma medicine to past and ongoing work in oncology. In the two extremes, cell death can be of tolerogenic or immunogenic nature. The latter is capable of inducing an immune response (immunogenic cell death, ICD). ICD is associated with tumor-reactive T cells, which are positively linked to survival in cancer patients. Several physical treatment modalities were shown to be potent ICD inducers, for example, ionizing radiation, and hyperthermia. Recent reports suggest that cold plasma may also increase the immunogenicity of cancer cells. This book chapter describes current concepts of immunity in oncology, sheds light on physical therapies in ICD, outlines current research in plasma-induced immunogenic cell death (PICD), and provides an outlook on future research and directions necessary to provide potential therapeutic benefit of plasma treatment in oncology.

Metrics

16 Record Views

Details

Logo image